Eugene Cone, MD, discusses SWOG S1602 findings comparing Tokyo-172 and TICE BCG and the potential role of alternative BCG strains in NMIBC
|Videos|May 11, 2021
Dr. Kate Kraft discusses her path to urology
Author(s)Urology Times staff
“I really fell in love with [urology] from the get go,” Kraft says.
Advertisement
In this video, Kate H. Kraft, MD, also shares her advice for female medical students who are considering pursuing urology. Kraft is an assistant professor of urology and residency program director for urology at the University of Michigan, Ann Arbor.
Advertisement
Related to this article
Juan Gómez-Rivas, MD, discusses barriers to PSMA-PET imaging and how disparities in access may affect prostate cancer staging and treatment planning.
Jonathan Harper, MD, discusses findings from the PUSH trial may inform counseling on hydration and stone recurrence.
Cameron C. Jones, MD, discusses patient selection for Aquablation, including prostate size, anatomy, and factors that may favor alternative BPH procedures.
Andrew Peterson, MD, discusses the quality-of-life impact of post-cancer incontinence and advances in electronically controlled artificial urinary sphincters.
In this episode, Karen Bigman, MBA, joins to discuss sexual health, intimacy, and relationship challenges facing adults as they navigate midlife and beyond.
John P. Sfakianos, MD, discusses the challenges of managing recurrent LG-IR-NMIBC and the role of chemoablation.
Rising patient interest in TRT, GLP-1s, and peptide stacking requires clinicians to anchor conversations in evidence tiers, use baseline DEXA scans to monitor body composition, and engage patient goals without endorsing unsupported claims.
Advertisement
Advertisement
Trending on Urology Times
1
FAQs: The 2026 AUA Guideline on Medical Management of Kidney Stones
2
The UroOnc Minute: Neoadjuvant Therapy Before Radical Prostatectomy, With Isaac Y. Kim, MD, PhD, MBA
3
PSMA-PET in clinical practice: Juan Gómez Rivas, MD, on barriers to access
4
CHMP recommends perioperative enfortumab vedotin plus pembrolizumab for MIBC
5